Study S002159

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT02477969
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: UNKNOWN
Enrollment: 587
Start: 2014-02-27
Primary completion: 2016-06-22
Lead sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:PEX168(100µg); DRUG:PEX168(200µg); DRUG:Placebo; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

HbA1c [Baseline to Week24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.